Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to explore the effectiveness of processed human amniotic fluid as a treatment for COVID-19.
Description: Assess reduction of inflammation in COVID-19 patients, potentially leading to a decrease in the need for critical care. This will be assessed by measurement of C-reactive protein levels before and after the intervention. Units: mg/dL
Measure: C-reactive protein Time: Baseline through post-treatment (6 days)Description: Comparison of mortality between intervention and control groups
Measure: Death within 30 Days Time: Baseline through 30 daysDescription: Comparison of days spend in ICU between intervention and control groups
Measure: ICU-free days at 30 days Time: Baseline through 30 daysDescription: Comparison of days spent in hospital between intervention and control groups
Measure: Hospital length of stay Time: From date of hospital admission through date of discharge or death, whichever comes first (up to 100 days)Description: Comparison of mechanical ventilation incidence between intervention and control groups
Measure: Need for invasive mechanical ventilation Time: From date of enrollment through date of discharge or death, whichever comes first (up to 100 days)Description: Comparison of mean biomarker level change between intervention and control groups. Units: pg/mL
Measure: Biomarker levels (interleukin-6) Time: Baseline through post-treatment (6 days)Description: Comparison of mean biomarker level change between intervention and control groups. Units: ug/mL
Measure: Biomarker levels (d-dimer) Time: Baseline through post-treatment (6 days)Description: Comparison of mean biomarker level change between intervention and control groups. Units: u/L
Measure: Biomarker levels (lactate dehydrogenase) Time: Baseline through post-treatment (6 days)Description: Comparison of ECMO incidence between intervention and control groups
Measure: Need for ECMO Time: From date of enrollment through date of discharge or death, whichever comes first (up to 100 days)Description: Compare frequency of major adverse cardiac events (MACE) between intervention and control groups
Measure: Major adverse cardiac events Time: From date of enrollment through date of discharge or death, whichever comes first (up to 100 days)Description: Comparison of PROMIS (Patient-Reported Outcomes Measurement Information System) questionnaire results on a computer-adaptive platform between intervention and control groups using T-scores. Scale mean = 50, standard deviation = 10.
Measure: Patient-reported functional status Time: Administered at 1, 3, 6, and 12 months post discharge (1 year)Description: Patients will be administered a 20-question self-report measure of PTSD symptoms. Total scores range from 0-80. Scores of 31-33 or above generally indicate clinically likely PTSD.
Measure: PTSD Checklist Time: Administered at 1, 3, 6, and 12 months post discharge (1 year)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports